IAV H5 Subtype HA Specific Neutra™ Antibody Products
Product listAre you facing the high pathogenicity of avian influenza viruses or the urgent need for reliable tools for vaccine efficacy evaluation and therapeutic development? Creative Biolabs' IAV H5 Subtype HA Specific Neutra™ Antibody Products empower your research with high-affinity, rigorously validated neutralizing antibodies, engineered through advanced recombinant technology and epitope-focused design to accelerate your antiviral discovery and diagnostic pipeline.
Introduction to Influenza A Virus H5 Subtype Hemagglutinin
Influenza A virus H5 subtype hemagglutinin (IAV H5 Subtype HA) is a pivotal surface glycoprotein that mediates viral entry into host cells, serving as the primary target for neutralizing antibodies and a key determinant of viral antigenicity and interspecies transmission. IAV H5 Subtype HA is a type I transmembrane protein synthesized as a precursor (HA0) that is cleaved by host proteases into HA1 and HA2 subunits, a step essential for viral infectivity. It is highly variable, with evolution driven by antigenic drift and shift, posing significant challenges for vaccine design.
- Structural Insights
The HA trimer comprises a globular head domain (HA1) containing the receptor-binding site (RBS) for sialic acids and a stem region (HA2) responsible for membrane fusion. Cryo-EM structures reveal conserved epitopes in the stem domain, which are crucial for the development of broadly neutralizing antibodies.
Fig.1 Schematic representation of the composition of an IAV particle.1
- Resistance and Signaling Pathways
Viral entry via HA binding activates host cell endocytic pathways and pH-dependent conformational changes. While HA itself is not a direct drug target, mutations in the RBS and cleavage site can confer resistance to neutralizing antibodies and enhance viral fitness, highlighting the need for antibodies targeting conserved regions.
H5 HA (e.g., H5N1) typically binds to α2,3-linked sialic acids, triggering viral entry via clathrin-mediated endocytosis or macropinocytosis. Upon internalization, H5 HA activation induces robust MAPK/ERK and PI3K/Akt signaling, which are essential for viral ribonucleoprotein (vRNP) nuclear import. Notably, H5 HA signaling often leads to a "cytokine storm" by hyper-activating the p38 MAPK and NF-κB pathways, resulting in excessive proinflammatory cytokine production and significant lung epithelial damage compared to low-pathogenic strains.
- Clinical Impact
H5N1 avian influenza viruses cause severe respiratory disease in humans, with high mortality rates. Their pandemic potential stems from zoonotic transmission and the lack of pre-existing immunity in human populations.
- Antibodies Against IAV H5 Subtype HA
Neutralizing antibodies targeting IAV H5 Subtype HA primarily inhibit viral entry by blocking receptor binding or preventing membrane fusion. Antibodies recognizing conserved epitopes, particularly in the stem region, are prioritized for their potential to counteract antigenic variation and provide broad protection.
Applications of Anti-IAV H5 Subtype HA Neutralizing Antibodies
Fig.2 A lineage of antibodies exhibiting cross-reactivity to both H3N2 and H1N1 subtypes was established.2
- Vaccine Efficacy and Immunogenicity Assessment
Anti-HA neutralizing antibodies are indispensable for evaluating vaccine candidates. Hemagglutination inhibition (HI) and microneutralization assays utilizing these antibodies quantify functional immune responses, correlate protection titers, and identify antigenic drift. This enables rapid assessment of vaccine immunogenicity against circulating H5 strains, guiding vaccine strain selection and dose optimization for pandemic preparedness.
- Therapeutic Development for Severe Influenza
Monoclonal antibodies targeting conserved HA epitopes offer a promising therapeutic strategy against H5N1 infection. In preclinical models, such antibodies reduce viral load in the respiratory tract, mitigate cytokine-driven pathology, and improve survival rates. Their passive administration can provide immediate protection for high-risk individuals and serve as a treatment option where antiviral resistance is a concern.
- Diagnostic and Surveillance Applications
High-specificity anti-HA antibodies are utilized in rapid immunoassays (e.g., ELISA, immunofluorescence) to detect H5 subtype viruses in clinical and environmental samples. This supports early outbreak detection, seroprevalence studies, and wildlife surveillance, which are critical for monitoring viral evolution and implementing timely public health interventions.
Our Anti-IAV H5 Subtype HA Specific Neutra™ Antibody Products
Creative Biolabs' antibody portfolio is designed to meet the highest standards of influenza research and development:
- High Neutralization Potency: Antibodies are functionally validated in pseudovirus and live virus neutralization assays, ensuring reliable biological activity.
- Epitope-Diverse Portfolio: Includes antibodies targeting both variable head domains and conserved stem regions.
- Rigorously Validated for Multiple Applications: Optimized and tested for performance in ELISA, Western Blot, Immunofluorescence, and Hemagglutination Inhibition assays.
- Consistent and Reproducible Supply: Produced under stringent quality control to ensure batch-to-batch consistency for long-term research projects.
Drawing on more than twenty years of experience in antibody engineering and virology, Creative Biolabs is committed to providing cutting-edge research tools that accelerate scientific discovery. Our IAV H5 Subtype HA Specific Neutra™ Antibody Products combine deep scientific insight with robust technical validation, offering researchers reliable solutions to combat highly pathogenic avian influenza. Contact our scientific team today to discuss your specific project needs and request detailed product specifications.
References
- Husain, Matloob. "Influenza A Virus H5N1 Subtype: Resurgent Interspecies and Intercontinental Transmission, and a New Host." Pathogens 15.1 (2025): 6. Distributed under Open Access license CC BY 4.0, without modification. Doi: https://doi.org/10.3390/pathogens15010006
- Sun, Xiaoyu, et al. "Unique binding pattern for a lineage of human antibodies with broad reactivity against influenza A virus." Nature communications 13.1 (2022): 2378. Distributed under Open Access license CC BY 4.0, without modification. Doi: https://doi.org/10.1038/s41467-022-29950-w
